首页 > 市场调查报告书 > 製药

疫苗

市场调查报告书

商品编码

1738665

全球结合疫苗市场规模（按类型、适应症、病原体、患者类型、地区、范围和预测）

Global Conjugate Vaccine Market Size By Type, By Disease Indication, By Pathogen Type, By Patients Type, By Geographic Scope And Forecast

出版日期: 2025年05月02日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

结合疫苗市场规模及预测

结合疫苗市场规模预计在 2024 年达到 167 亿美元，到 2032 年将达到 382.7 亿美元，2026 年至 2032 年的复合年增长率为 11%。

结合疫苗是次单位疫苗，专门设计用于针对细菌表面的弱抗原产生更强的免疫反应。
结合疫苗可以诱导免疫记忆并减少无症状性的细菌携带者，从而产生大量的群体免疫。
目前已利用肺炎链球菌多醣体开发了结合疫苗，其中7价、9价甚至11价疫苗已进入临床试验阶段；针对A群和C群脑膜炎球菌的结合疫苗也正在研发中，但针对B群脑膜炎双球菌的结合疫苗仍存在挑战。
结合疫苗有三种：C群脑膜炎双球菌结合疫苗（MnCC）、b型流感嗜血桿菌结合疫苗（Hib）和肺炎链球菌结合疫苗（PnC）。
肺炎链球菌结合疫苗可以预防引起肺炎链球菌疾病的细菌。肺炎链球菌结合疫苗有三种：PCV13、PCV15 和 PCV20。

全球结合疫苗市场动态

关键市场驱动因素

婴幼儿早期保护：改善启动免疫是其主要优点之一。与传统免疫接种不同，结合疫苗能够更好地在免疫系统尚在发育的新生儿和幼儿中引发免疫反应（即抗体反应，尤其是IgG1抗体）。这使得在关键发育阶段能够更早预防疾病。
持久免疫力和增强免疫力：含有结合物的疫苗能够有效活化免疫系统的记忆。它们能够刺激长寿记忆B细胞的增殖。即使多年后再次接触同一种细菌，这些记忆B细胞也能记住特定抗原，并立即产生强烈的免疫反应。如果您再次接种疫苗，这将起到增强免疫力的作用。
黏膜保护：除了常规疫苗主要针对的血流抗体生成外，结合疫苗还能诱发分泌型IgA和黏膜活性IgG抗体的合成。黏膜表面是人体抵抗多种疾病的第一道防线，而这些特化抗体对此防御至关重要。
更佳疗效和精准标靶：结合疫苗促进「亲和性成熟」过程，这意味着免疫系统逐渐提高抗体的产生能力，从而提高抗体对目标抗原的亲和性（结合更紧密）。更紧密的结合增强了抗体的调理作用，标记出细菌以便免疫细胞清除，从而提高疫苗的有效性。
显着减少Hib和肺炎球菌性脑膜炎：目前，针对PCV和Hib（b型流感嗜血桿菌）的疫苗接种在预防儿童脑膜炎方面非常有效。结合疫苗接种在促进群体免疫方面发挥了重要作用，因为它减少了持有病菌但无症状的人数。这意味着即使未接种疫苗的人也能受到保护，因为带因者人数减少意味着人口感染风险降低。
急性中耳炎和社区型肺炎发生率增加：这些疫苗具有广泛的功效，不仅可以预防脑膜炎和败血症等危险且侵袭性的疾病，还能有效治疗常见的良性疾病。接种结合疫苗可显着降低成人和儿童急性中耳炎（耳部感染疾病）和社区型肺炎的发生率。这些结果表明，未来优化预防策略可能会使社区更加健康。肺炎链球菌性肺炎每年在美国导致15万人住院，死亡率为5-7%。

主要挑战

成本与可负担性：结合疫苗的研发和生产成本通常高于传统疫苗。这些成本的增加导致每剂疫苗价格上涨，这可能会限制其在新兴国家的普及。此外，结合疫苗等现代昂贵疫苗成本过高且研发不足，无法由政府资金承担，新兴国家无力负担研发和购买疫苗的费用。
基础设施有限且低温运输挑战：有效分发结合疫苗需要强大的低温运输基础设施，以确保整个供应链的储存温度适宜。在南非、中东和亚洲等资源和基础设施有限的地区，这可能是一个严重的问题，导致疫苗劣化和效力降低。例如，在印度，1-59个月龄儿童的肺炎死亡率为12%，婴儿肺炎死亡率为3%。
公众认知与疫苗犹豫：错误讯息和疫苗接种疑虑可能会阻碍结合疫苗的接种。透过教育和宣传宣传活动解决公众担忧，对于消除疫苗犹豫并确保尽可能高的接种率至关重要。
不断变化的细菌血清型和菌株：某些细菌，例如肺炎链球菌，具有不同的血清型和菌株。儘管结合疫苗针对的是特定的血清型，但疫苗无法预防的新发或新菌株仍构成危险。为了应对这个问题，研究人员必须持续开发针对新型血清型或具有更广泛效力的疫苗。例如，大约75%的侵袭性肺炎球菌疾病和83%的肺炎球菌脑膜炎病例发生在儿童身上。

主要趋势：

改善儿童免疫接种计划的需求不断增长：市场需求的驱动力源于人们对结合疫苗益处的认识不断加深，尤其是其保护婴幼儿免受致命感染疾病的能力。低度开发国家对改善儿童免疫系统的日益关注，为市场成长开闢了新的途径。例如，在印度，到2020年，约90%的儿童将能够接种救命疫苗。
扩大疫苗靶向：研发目标是开发能够应对更多种类感染疾病的结合疫苗。这包括持续研发免疫接种，以预防由不同脑膜炎球菌菌株和新型肺炎球菌血清型引起的脑膜炎等疾病。
技术发展：改进的疫苗生产方法正在创造更有效、更实惠的结合疫苗。这可能会使疫苗更容易取得且价格更实惠，尤其是在资源有限的地区。借助基因编辑等新技术，可以开发出具有更高免疫抗原性或更广泛保护作用的新型结合疫苗。

A conjugate vaccine is a subunit vaccine that is designed to elicit a stronger immune response against weak antigens, especially those found on the surface of bacteria.
The conjugate vaccine is capable of substantially eliciting herd immunity by inducing immunological memory and lowering the bacteria's asymptomatic carriage.
Conjugate vaccines are being developed using pneumococcal polysaccharides, with 7, 9, and even 11-valent versions undergoing clinical trials, and conjugate vaccines targeting meningococcal groups A and C, but the group B meningococcal presents a challenge.
Conjugate vaccines are available in three types Meningococcal Group C Conjugate (MnCC), Hemophilus Influenzae Type b (Hib), and Pneumococcal Conjugate (PnC).
Pneumococcal conjugate vaccine helps protect against bacteria that cause pneumococcal disease. There are three pneumococcal conjugate vaccines (PCV13, PCV15, and PCV20).

Global Conjugate Vaccine Market Dynamics

The key market dynamics that are shaping the global Conjugate Vaccine Market include:

Key Market Drivers

Early Protection for Infants: Improved priming is one of the main benefits. Contrary to some conventional vaccinations, conjugate vaccines can successfully elicit an immune response in newborns and young children whose immune systems are still developing (i.e., an antibody response, specifically IgG1 antibodies). This enables earlier illness prevention throughout crucial developmental phases.
Long-Term Immunity & Booster Effect: Vaccines containing conjugates are excellent at igniting the memory of the immune system. They encourage the growth of memory B cells with a long lifespan. When the same germs are encountered again, even years later, these memory cells can quickly mount a potent immune response because they can recall the particular antigen. When obtaining a revaccination, this translates to a booster effect that strengthens immunity even more.
Mucosal Protection: Conjugate vaccines can induce secretory IgA and mucosally active IgG antibody synthesis, in addition to the bloodstream antibody production that is the main target of traditional vaccines. Mucosal surfaces are the body's first line of defense against numerous illnesses, and these particular antibodies are essential for their protection.
Better Effectiveness and Precise Targeting: Conjugate vaccinations encourage the "affinity maturation" process. This indicates that as a result of the immune system's gradual improvement in antibody production, the resulting antibodies have a higher affinity (tighter binding) to the target antigen. The opsonizing function, in which antibodies mark bacteria for eradication by immune cells, is improved by this closer match, thus increasing the vaccine's efficacy.
Significant Reduction in Hib and Pneumococcal Meningitis: The current vaccinations against PCV and Hib (Haemophilus Influenzae type b) are exceptionally successful in avoiding childhood meningitis. Conjugate vaccinations play a major role in promoting herd immunity by lowering the number of people who carry bacteria but do not exhibit any symptoms. This implies that even individuals who have not received vaccinations are protected since fewer carriers equate to a lower risk of transmission within the population.
Rising Incidence of Acute Otitis Media and Community-Acquired Pneumonia: These vaccines have far-reaching effects that go well beyond shielding against dangerous, invasive illnesses like meningitis and sepsis. They are incredibly successful in treating common benign ailments. Conjugate vaccinations considerably lower the incidence of acute otitis media (ear infections) and community-acquired pneumonia in both adults and children. These results pave the way for promising future prevention strategy optimizations that could result in even healthier communities. In the United States every year 150,000 people are hospitalized for Pneumococcal pneumonia and the mortality rate is 5%-7%.

Key Challenges:

Cost and Affordability: Compared to regular vaccines, conjugate vaccines are frequently more expensive to research and produce. This increased expense may result in a higher price per dosage, which can restrict accessibility in emerging countries. In addition, the expense of more recent and costly vaccines, such as conjugate vaccines, are not covered by government funding as the vaccines are expensive and underdeveloped, and developing countries cannot afford the cost of vaccine research and purchase.
Limited Infrastructure and Cold Chain Challenges: To ensure appropriate storage temperatures across the supply chain, effective conjugate vaccine delivery necessitates a strong cold chain infrastructure. In areas with inadequate resources or infrastructure, such the regions like South Africa, and Middle East, and Asia this can pose a serious problem and result in vaccine deterioration and decreased efficacy, which is expected to hamper the growth of the Conjugate Vaccine Market in the underdeveloped and developing regions. For instance, the mortality rate in developing regions is increasing, such as in India children with age 1-59 months affected by pneumonia have a 12% mortality rate, and infants affected have a 3% mortality rate.
Public Perception and Vaccine Hesitancy: The widespread use of conjugate vaccines may be hampered by misinformation and skepticism about vaccinations. To combat vaccine hesitancy and guarantee the highest possible immunization rates, it is imperative to address public concerns through campaigns of education and awareness.
Changing Bacterial Serotypes and Strains: Some bacteria, such as pneumococcus, have different serotypes and strains. Conjugate vaccinations target particular serotypes, but emerging or novel strains that are not protected by the vaccine can still be dangerous. To remain ahead of this problem, researchers must continue to create vaccinations that target novel serotypes or vaccines with a wider spectrum of effects. For instance, about 75% of invasive pneumococcal disease and 83% of pneumococcal meningitis occur in children.

Key Trends:

Growing Demand for Better Childhood Immunization Programs:Demand in the market is being driven by rising knowledge of the advantages of conjugate vaccinations, particularly their capacity to protect young infants against deadly infections. Growing attention to improving childhood immunization systems in underdeveloped nations opens up new avenues for market growth. For instance, in India around 90% of children have access to life-saving vaccines till 2020.
Increased Vaccine Targets: The goal of research and development is to create conjugate vaccines that can combat a larger variety of infections. This involves the continuous creation of vaccinations to prevent illnesses like meningitis brought on by different meningococcal strains and novel pneumococcal serotypes.
Technological Developments: More effective and reasonably priced conjugate vaccines are being created as a result of improvements in vaccine production methods. This could increase accessibility and affordability, especially in environments with limited resources. Novel combination vaccines with enhanced immunogenicity or wider protection could be developed with the help of emerging technologies like gene editing.

Global Conjugate Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the global Conjugate Vaccine Market:

North America

North America is known for its fast-paced atmosphere, which facilitates the rapid adoption of vaccination breakthroughs. This flexibility makes it possible to increase the development of vaccines and investigate novel solutions with more ease. This is in contrast to certain regions of Europe and Asia where adoption rates may be lower.
Public healthcare systems that are well-developed and provide extensive coverage for medical services are found throughout North America. Strong assistance is extended to vaccine research and development (R&D) endeavors. This encourages creativity and concentrates attention on enhancing public health via immunization campaigns. For instance, in the U.S. in 2022 around 9% of children ages 6 months to 17 years have been vaccinated by influenza vaccination during the past 12 months.
An established healthcare system and the existence of large pharmaceutical companies offer a solid basis for the conjugate vaccination industry in North America. The region's supremacy in this sector is mostly due to these factors. For instance, in 2021, the United States spent around 17.8 & of the gross domestic product on healthcare.
The increasing prevalence of influenza in the U.S. is propelling the growth of the Conjugate Vaccine Market. For instance, in 2023 around 121 children died due to influenza. According to the Centers for Disease Control and Prevention, at least 30 Million people are affected 340,00 are hospitalized, and 21,000 deaths due to the flu.

Asia-Pacific

Asia-Pacific is the fastest-growing region in the Conjugate Vaccine Market during the forecast period due to the increasing population and government initiatives for healthcare infrastructure.
In Asia-Pacific, the population is expanding quickly in many of the member states. This generates a great deal of demand, especially for youngsters, for greater vaccination coverage. Given their efficacy in defending young infants, conjugate vaccinations are ideally positioned to meet this requirement.
For instance, in India in 2022-23 cases reported of pneumonia in the states are Maharashtra (14078), Assam (11011), Jammu and Kashmir (4952), Madhya Pradesh (39948), Punjab (14965) etc.
Increasing the prevalence of conjugate vaccines the government is actively taking initiatives such as funding immunization campaigns and investment in research and development. For instance, in India from 2015 to 2020 the immunization coverage in children from the age of 12-23 months is estimated to be 62% in 2015-2016 to 76% in 2019-2020.

Global Conjugate Vaccine Market: Segmentation Analysis

The Global Conjugate Vaccine Market is segmented on the basis of Type, Disease Indication, Pathogen Type, Patient Type, and Geography.

Conjugate Vaccine Market, By Type

Monovalent Conjugate Vaccines
Multivalent Conjugate Vaccines

Based on Type, the market is segmented into Monovalent Conjugate Vaccines and Multivalent Conjugate Vaccine. The Multivalent Conjugate Vaccines segment is substantially leading in the Conjugate Vaccine Market and is expected to continue its growth during the forecast period. A significant breakthrough in the battle against infectious illnesses has been made with the development of multivalent conjugate vaccines. Their capacity to offer more comprehensive protection, economy, and effectiveness is propelling market expansion and clearing the path for a healthier future. Technological developments along with encouraging policy measures from the government will probably ensure that multivalent conjugate vaccines continue to dominate the conjugate vaccine industry.

Conjugate Vaccine Market, By Disease Indication

Pneumococcal
Influenza
DTP
Meningococcal
Typhoid

Based on Disease Indication, the market is segmented into Pneumococcal, Influenza, DTP, Meningococcal, and Typhoid. The increasing prevalence of DTP in children globally is fueling the growth of DTP vaccines all over the world. For instance, in 2022, around 86% and in 2021 around 89% the coverage of DTPcv1 has increased globally and similarly the coverage of DTPcv3 has increased from 81% in 2021 and 84% in 2022. To ensure that children everywhere have a healthier future, ongoing initiatives to increase vaccination rates, broaden immunization programs, and discover novel vaccines are essential. DTP vaccine segments in the Conjugate Vaccine Market emphasize how important these vaccinations are in shielding kids from potentially fatal diseases.

Conjugate Vaccine Market, By Pathogen Type

Bacterial Conjugate Vaccine
Viral Conjugate Vaccine
Combination (Viral And Bacterial) Conjugate Vaccine

Based on Pathogen Type, the market is segmented into Bacterial Conjugate Vaccine, Viral Conjugate Vaccine, and Combination (Viral And Bacterial) Conjugate Vaccine. Bacterial Conjugate Vaccine is significantly leading the Conjugate Vaccine Market. These vaccinations target bacteria specifically, which is a single-celled organism that can cause a variety of diseases. Bacterial conjugate vaccines directly target the bacteria, in contrast to toxoid vaccinations, which concentrate on inactivated bacterial toxins.

Conjugate Vaccine Market, By Patient Type

Pediatric
Adults

Based on Patient Type, the market is segmented into Pediatric and Adults. Pediatric segment is substantially leading in the Conjugate Vaccine Market. Hib meningitis is a severe infection that can be fatal for young children. The Hib conjugate vaccine has significantly reduced the burden of this disease. In children, pneumococcal bacteria are the primary cause of sepsis, meningitis, and pneumonia. PCV vaccinations provide essential defense against several infections.

Key Players

The "Global Conjugate Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Bharat Biotech, Biological E, CSL Limited, Glaxo SmithKline, plc., Merck and Company, Bio-Rad, Novartis AG, Pfizer Inc., Sanofi Pasteur, and Serum Institute of India. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Conjugate Vaccine Market Recent Developments
In August 2022, Nigeria announced a vaccine of Bharat Biotech for the immunization of children. Reducing the infectious disease burden amongst children in the developing world, and ensuring nations like Nigeria in the African continent, have access to cost-effective world-class interventions for infants and vulnerable populations. ROTAVAC(R) is safe and effective at preventing diarrheal disease caused by the Rotavirus."
In July 2023, the Serum Institute of India announced the first conjugate vaccine that protects from the predominant causes of meningococcal meningitis in Africa, has been prequalified by the World Health Organization (WHO). MenFive(R) is a vaccine that protects against meningococcal serogroups A, C, W, Y, and X. It was developed over 13 years of collaboration between Serum Institute of India Pvt. Ltd. and PATH, with significant funding from the Foreign, Commonwealth and Development Office of the UK government.

1. Introduction

Market Definition
Market Segmentation
Research Methodology

2. Executive Summary

Key Findings
Market Overview
Market Highlights

3. Market Overview

Market Size and Growth Potential
Market Trends
Market Drivers
Market Restraints
Market Opportunities
Porter's Five Forces Analysis

4. Conjugate Vaccine Market, By Type

Monovalent Conjugate Vaccines
Multivalent Conjugate Vaccines

5. Conjugate Vaccine Market, By Disease Indication

Pneumococcal
Influenza
DTP
Meningococcal
Typhoid

6.Conjugate Vaccine Market, By Pathogen Type

Bacterial Conjugate Vaccine
Viral Conjugate Vaccine
Combination (Viral And Bacterial) Conjugate Vaccine

7.Conjugate Vaccine Market, By Patient Type

Pediatric
Adults

8. Regional Analysis

North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Asia-Pacific
China
Japan
India
Australia
Latin America
Brazil
Argentina
Chile
Middle East and Africa
South Africa
Saudi Arabia
UAE

9. Market Dynamics

Market Drivers
Market Restraints
Market Opportunities
Impact of COVID-19 on the Market

10. Competitive Landscape

Key Players
Market Share Analysis

11. Company Profiles

Bharat Biotech
Biological E
CSL Limited
Glaxo SmithKline, plc.
Merck and Company
Bio-Rad
Novartis AG
Pfizer Inc.
Sanofi Pasteur
Serum Institute of India

12. Market Outlook and Opportunities

Emerging Technologies
Future Market Trends
Investment Opportunities

13. Appendix

List of Abbreviations
Sources and References

02-2729-4219

+886-2-2729-4219

License/价格

全球结合疫苗市场规模（按类型、适应症、病原体、患者类型、地区、范围和预测）

Global Conjugate Vaccine Market Size By Type, By Disease Indication, By Pathogen Type, By Patients Type, By Geographic Scope And Forecast

结合疫苗市场规模及预测

全球结合疫苗市场动态

关键市场驱动因素

目录

第一章 引言

第二章执行摘要

第三章市场概述

4. 结合疫苗市场（按类型）

5. 结合疫苗市场（按适应症）

6. 结合疫苗市场（依病原体类型）

7. 结合疫苗市场（依患者类型）

第八章区域分析

第九章市场动态

第十章 竞争格局

第十一章 公司简介

第十二章 市场展望与机会

第十三章 附录

Conjugate Vaccine Market Size And Forecast